Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5^th Avenue in New York City. Please click here to register for the event.

The event will feature a comprehensive overview of our platforms and the latest developments in our pipeline through presentations from members of Legend’s senior leadership team:

• Ying Huang, Ph.D., Chief Executive Officer
• Guowei Fang, Ph.D., Senior Vice President, Global Head of Research and Early Development
• Lida Pacaud, M.D., Vice President, Clinical Development
• Steve Gavel, Vice President, Commercial Development, US & Europe

A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech website under “Events and Presentations”. A replay of the webcast can be viewed as early as 24 hours after the event.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Source: Legend Biotech